Profile: Actavis PLC (ACT)

ACT on New York Consolidated

260.90USD
17 Dec 2014
Price Change (% chg)

$4.38 (+1.71%)
Prev Close
$256.52
Open
$257.76
Day's High
$261.20
Day's Low
$254.56
Volume
2,860,943
Avg. Vol
3,081,268
52-wk High
$272.75
52-wk Low
$156.40

Search Stocks

Actavis PLC, incorporated on May 16, 2013, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes. The Company's product formulations include modified release, solid oral dosage, semi-solids, suspensions, transdermals, suppositories, creams, ointments, liquids and injectables. In July 2014, the Company acquired Forest Laboratories, Inc. In July 2014, the Company acquired Furiex Pharmaceuticals, Inc. In July 2014, Impax Laboratories Inc acquired from Actavis plc two generic products.

The Company’s Actavis Pharma business manufactures, markets and distributes products therapeutic categories, which include Antibiotics, Anti-inflammatories, Cardiovascular Diseases, Dermatology Products, Central Nervous System Disorders, Metabolic Disorders, Musculo-skeletal System Disorders, Respiratory System Treatments and Contraceptives. Actavis Specialty Brands is the Company’s global branded specialty pharmaceutical business focused in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories. Actavis Specialty Brands also has a portfolio of five biosimilar products in development in Women's Health and Oncology.

Company Address

Actavis PLC

1 Grand Canal Square
Dublin 2, Docklands
DUBLIN     07054

Search Stocks